Tenofovir vs lamivudine for the prevention of hepatitis B virus reactivation in advanced-stage DLBCL

Blood. 2019 Jan 31;133(5):498-501. doi: 10.1182/blood-2018-10-878892. Epub 2018 Dec 7.

Affiliations

¹ Department of Advanced Biomedical Sciences and.
² Department of Clinical Medicine and Surgery, Federico II University Medical, School, Naples, Italy; and.
³ Department of Economics, University of Molise, Campobasso, Italy.

No abstract available

Publication types

Comparative Study
Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Antiviral Agents / therapeutic use*
Female
Hepatitis B virus / drug effects*
Hepatitis B, Chronic / complications
Hepatitis B, Chronic / prevention & control*
Humans
Lamivudine / therapeutic use*
Lymphoma, Large B-Cell, Diffuse / complications
Lymphoma, Large B-Cell, Diffuse / drug therapy
Lymphoma, Large B-Cell, Diffuse / virology*
Male
Middle Aged
Tenofovir / therapeutic use*
Virus Activation / drug effects
Young Adult

Substances

Antiviral Agents
Lamivudine
Tenofovir